The full-course therapy would cost an additional $21,337 per additional case of HIV infection averted (if the cost of drugs were $259) and an additional $27,010 per additional case of HIV infection averted (if the cost of drugs were $50). Full-course ZDV therapy was incrementally cost-saving compared to the shorter regimen provided that:
(1) the incremental cost is less than $3,265;
(2) the incremental effectiveness exceeds 3.9%;
(3) the cost of treating pediatric HIV/AIDS is greater than $21,337;
(4) the acceptance rate of the full-course regimen was at least 80.4% as large as the acceptance rate of the shorter regimen.